Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria.
Laboratory of Genomic Diagnostics, Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria.
Mol Genet Genomic Med. 2022 Aug;10(8):e1997. doi: 10.1002/mgg3.1997. Epub 2022 Jun 3.
Next-generation sequencing (NGS)-based method is being used broadly for genetic testing especially for clinically and genetically heterogeneous disorders, such as inherited retinal degenerations (IRDs) but still not routinely used for molecular diagnostics in Bulgaria. Consequently, the purpose of this study was to evaluate the effectiveness of a molecular diagnostic approach, based on targeted NGS for the identification of the disease-causing mutations in 16 Bulgarian patients with different IRDs.
We applied a customized NGS panel, including 125 genes associated with retinal and other eye diseases to the patients with hereditary retinopathies.
Systematic filtering approach coupled with copy number variation analysis and segregation study lead to the identification of 16 pathogenic and likely pathogenic variants in 12/16 (75%) of IRD patients, 2 of which novel (12.5%): ABCA4-c.668delA (p.K223Rfs18) and RР1-c.2015dupA (p.K673Efs*25). Mutations in the ABCA4, PRPH2, USH2A, BEST1, RР1, CDHR1, and RHO genes were detected reaching a diagnostic yield between 42.9% for Retinitis pigmentosa cases and 100% for macular degeneration, Usher syndrome, and cone-rod dystrophy patients.
Our results confirm the usefulness of targeted NGS approach based on frequently mutated genes as a comprehensive and successful genetic diagnostic tool for IRDs with significant impact on patients counseling.
下一代测序(NGS)方法广泛应用于基因检测,特别是针对遗传上和临床上具有异质性的疾病,如遗传性视网膜变性(IRDs),但在保加利亚尚未常规用于分子诊断。因此,本研究旨在评估基于靶向 NGS 的分子诊断方法在 16 名患有不同 IRD 的保加利亚患者中识别致病突变的有效性。
我们对遗传性视网膜病变患者应用了包含 125 个与视网膜和其他眼部疾病相关的基因的定制 NGS 面板。
系统的过滤方法结合拷贝数变异分析和分离研究,确定了 12/16(75%)IRD 患者的 16 个致病性和可能致病性变异,其中 2 个是新的(12.5%):ABCA4-c.668delA(p.K223Rfs18)和 RΡ1-c.2015dupA(p.K673Efs*25)。在 ABCA4、PRPH2、USH2A、BEST1、RΡ1、CDHR1 和 RHO 基因中检测到突变,视网膜色素变性病例的诊断率在 42.9%之间,黄斑变性、Usher 综合征和圆锥-杆营养不良患者的诊断率为 100%。
我们的结果证实了基于常见突变基因的靶向 NGS 方法作为一种全面且成功的 IRD 遗传诊断工具的有效性,对患者咨询具有重要影响。